Reference entry · Synthetic tripeptide bioregulator
Vesugen
Also known as: Lys-Glu-Asp · KED tripeptide bioregulator
- Class
- Synthetic tripeptide bioregulator
- Size
- 3 amino acids
- Primary targets (literature)
- Endothelial and vascular aging literature
- Regulatory context
- Not FDA-approved. Vascular preclinical findings are not cardiovascular treatment claims.
Overview
Vesugen is a Lys-Glu-Asp tripeptide bioregulator studied in vascular and endothelial aging research from the Khavinson catalog. It is frequently discussed alongside cardiovascular recovery peptides but occupies a separate evidence base.
Mechanism in research literature
Published models explore endothelial cell function, vascular wall gene expression, and atherosclerosis-related markers in aging rodent paradigms.
Common research focus areas
- Endothelial cell culture and permeability assays
- Vascular aging and atherosclerosis rodent models
- Tripeptide identity vs. longer vascular peptides
- Cross-reference with angiotensin and VIP literature
Full literature roundup
Read the cited research summary
A Lys-Glu-Asp tripeptide bioregulator studied in vascular and endothelial aging models. What the Khavinson literature describes — and how it relates to cardiovascular research peptides.
Vesugen research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.